Skip to main content
. Author manuscript; available in PMC: 2015 Jan 22.
Published in final edited form as: Chem Rev. 2013 Dec 3;114(2):1020–1081. doi: 10.1021/cr400166n

Figure 9.

Figure 9

Vaccination with plasma membrane vehicles modified with the dendritic-cell-specific peptide CGRWSGWPADLC (p30) leads to antitumor activity. Naïve mice were injected iv with B16-OVA cells on day 0. At days 2, 8, and 14 different groups of mice (five mice per group) were vaccinated with PBS or B16-OVA-derived plasma membrane vehicles modified with the control peptide 12His or the dendritic-cell-specific peptide p30. At day 21, the lungs were removed from the mice, and tumor foci were counted via microscopy. (A) Bars indicate the mean number of tumor foci for each vaccination group, and this number is indicated above each bar. (B) Representative lung images from each vaccination group. Reprinted with permission from ref 391. Copyright 2010 Union for International Cancer Control (UICC).